| IBI-363 / Innovent Biologics |
NCT06281678: A Study of IBI363 in Subjects With Advanced Solid Malignancies |
|
|
| Recruiting | 2 | 160 | US | IBI363 | Innovent Biologics (Suzhou) Co. Ltd. | Solid Tumors | 03/26 | 12/26 | | |
NCT06620822: Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial |
|
|
| Not yet recruiting | 2 | 296 | RoW | IBI363, LM-108+Sintilimab, IBI310+Sintilimab, Sintilimab | Shanghai Pulmonary Hospital, Shanghai, China | Non Small Cell Lung Cancer | 09/26 | 09/27 | | |
NCT06081920: A Study of IBI363 in Subjects With Advanced Melanoma |
|
|
| Recruiting | 2 | 120 | RoW | IBI363 | Innovent Biologics (Suzhou) Co. Ltd. | Melanoma | 06/25 | 07/26 | | |
| Recruiting | 1/2 | 430 | RoW | IBI363, IBI325, Lenvatinib | Hunan Province Tumor Hospital, Xiangya Hospital of Central South University | Advanced Solid Tumor | 12/26 | 09/28 | | |
NCT05290597: A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas |
|
|
| Recruiting | 1 | 84 | RoW | IBI363 | Innovent Biologics (Suzhou) Co. Ltd. | Solid Malignancies or Lymphomas | 06/23 | 08/24 | | |
NCT05460767: Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma |
|
|
| Recruiting | 1 | 260 | RoW | IBI363 | Innovent Biologics (Suzhou) Co. Ltd. | Solid Tumors or Lymphoma | 03/24 | 12/24 | | |
| Recruiting | 1 | 556 | RoW | IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 06/25 | 12/26 | | |
NCT06610799: Study of IBI363 in Patients With Advanced First-line Gastric Cancer |
|
|
| Not yet recruiting | 1 | 40 | RoW | IBI363 | Xiangdong Cheng | IBI363 + Chemotherapy | 06/25 | 12/26 | | |
ChiCTR2400085937: A Phase I Study to Evaluate the Safety, and Efficacy of IBI363 in Patients with Metastatic or Locally Advanced Alveolar Soft Part Sarcoma. |
|
|
| Not yet recruiting | 1 | 40 | | IBI363: priming dose: 100μg/kg (C0), from C1D1: 3mg/kg,Q3W,Intravenous infusion; IBI363: priming dose: 100μg/kg (C0), from C1D1: 3mg/kg,Q3W,Intravenous infusion | Peking University Cancer Hospital; Peking University Cancer Hospital, Innovent Biologics(Suzhou)CO,Ltd | Alveolar Soft Part Sarcoma | | | | |
